[Market Watch] CVS officials say Sovaldi pricing in line with history, but unsustainable

Gilead Sciences’ controversial $1,000-a-day Sovaldi pill is priced in line with previous treatments for Hepatitis C, but the nation’s health-care system likely won’t be able to handle that kind of sticker shock, and competition probably will bring down that price tag in coming months and years.

Read More

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.